Clinical trials: Cancer of the Prostate
Prostatic Neoplasms
Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg
This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen…
- Trial name
- NCT02712320
- Testing
- LMIS 50 mg
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Prostate Cancer
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
Currently, there are no established 2nd-line or salvage chemotherapy regimens for patients with HRPC, many of whom retain an excellent performance status.
- Trial name
- NCT00545766
- Testing
- Vinflunine
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- SCRI Development Innovations, LLC
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of Chinese men with metastatic castration-resistant prostate cancer (mCRPC) who have not…
- Trial name
- NCT04907227
- Testing
- Pembrolizumab, Docetaxel, Prednisone
- Where
- 20 sites in China
- Volunteers
- 81 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients
To investigate the long-term safety and tolerability of repeated doses of degarelix to prostate cancer patients
- Trial name
- NCT00245466
- Testing
- Degarelix
- Volunteers
- 88 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
FACBC Prostate Therapy Response
The purpose of this study is to assess if using anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (FACBC or fluciclovine) PET scan will be useful in determining if participants are responding to chemotherapy treatment.
- Trial name
- NCT02830880
- Testing
- FACBC PET-CT, MRI, CT, or Bone Scan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Emory University
Hot Flashes
Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy
This study will look at the effects of a soy supplement called Revival on memory, quality of life, and hot flashes in men with prostate cancer who are being treated with testosterone suppression therapy.
- Trial name
- NCT00245518
- Testing
- Isoflavone
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Prostate Cancer, Interstitial Radiation
CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using Vitesse
High Dose Rate (HDR) temporary prostate brachytherapy offers a precise form of dose escalation for prostate cancer. Needles are placed, the position is confirmed and treatment is delivered.
- Conditions
- Prostate Cancer, Interstitial Radiation, High Dose Rate Brachytherapy, Ultrasound-based Planning Compared to CT-based Planning
- Trial name
- Vitesse (NCT01248741)
- Testing
- HDR prostate brachytherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
This study will look at the effect of adding the drug Palbociclib to CAD (Combined Androgen Deprivation) therapy in patients with RB (Retinoblastoma Protein) positive hormone sensitive prostate cancer.
- Trial name
- NCT02059213
- Testing
- Ibrance, Bicalutamide, Zoladex
- Where
- 8 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Squamous Cell Carcinoma, Breast Cancer
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma
- Trial name
- NCT02643303
- Testing
- Durvalumab, Tremelimumab, Poly-ICLC
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- Ludwig Institute for Cancer Research
Androgen Deprivation Therapy, Prostate Cancer
Contributions to Hypertension With Androgen Deprivation Therapy
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer.
- Conditions
- Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction
- Trial name
- ARCH (NCT05700903)
- Testing
- Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Vertebral Metastasis
Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine
The purpose of this study is to determine if Conformal High Dose Intensity Modulated Radiation Therapy is an appropriate option for treating cancer that has spread to the spinal column.
- Trial name
- NCT01654068
- Testing
- Conformal High Dose Intensity Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Ronald McGarry
Metastatic Castration Resistant Prostate Cancer
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
- Trial name
- RAMP (NCT04179396)
- Testing
- Rucaparib, Enzalutamide, Abiraterone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- pharmaand GmbH
Prostate Carcinoma
Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
This randomized pilot clinical trial studies how well propranolol hydrochloride works in treating patients with prostate cancer who are undergoing surgery.
- Trial name
- NCT03152786
- Testing
- Laboratory Biomarker Analysis, Propranolol Hydrochloride, Questionnaire Administration
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer, Prostatic Cancer
CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer.
- Conditions
- Prostate Cancer, Prostatic Cancer, Prostate Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00643994
- Testing
- CyberKnife Stereotactic Radiosurgery
- Where
- 23 sites in United States
- Volunteers
- 379 people
- Sponsor
- Accuray Incorporated
Prostate Cancer
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Interstitial brachytherapy uses radioactive material placed directly into or near a tumor to kill tumor cells.
- Trial name
- NCT00063882
- Testing
- Brachytherapy (100/110), Brachytherapy (125/145), External Beam Radiation Therapy
- Where
- 170 sites in United States, Canada
- Volunteers
- 588 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Castration Resistant Prostate Cancer
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease…
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Trial name
- COMET-1 (NCT01605227)
- Testing
- cabozantinib, prednisone
- Where
- 264 sites in United States, Australia and 12 more
- Volunteers
- 1,028 people
- Sponsor
- Exelixis
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with…
- Trial name
- NCT01054079
- Testing
- laboratory biomarker analysis, quality-of-life assessment, questionnaire administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.
- Trial name
- NCT01317641
- Testing
- ODM-201
- Where
- 23 sites in United States, Czechia and 4 more
- Volunteers
- 136 people
- Sponsor
- Orion Corporation, Orion Pharma
Metastatic Hormone-Sensitive Prostate Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in Chinese participants with mHSPC.
- Trial name
- NCT04934722
- Testing
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 24 sites in China
- Volunteers
- 186 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
We postulate that multiple apoptototic events are indusce through testosterone depletion and repletion with taxotere given in conjunction with androgen withdrawal.
- Trial name
- NCT00587431
- Testing
- GnRh (Leuprolide), Testosterone Gel, Docetaxel
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.